Xofigo, a newly approved treatment for advanced prostate cancer that has spread to the bones, is said to reduce patient pain levels. The drug, which mimics calcium by binding to bone tissue at tumor sites, has been shown to extend patient survival rates by three months. The binding action of Xofigo allows physicians to target the precise location of bone tumors caused by prostate cancer, and minimizes bone damage caused by tumors. It is reported that Xofigo may allow patients to delay chemotherapy and the use of morphine for pain management. A Xofigo treatment can be administered in a few as 15 minutes.
This prostate cancer news is brought to you by UroSciences– makers of the UroStop variable tension penile loop for sexual incontinence and the PDAD Peyronie’s disease assessment device.
Tags: advanced prostate cancer, PDAD, Peyronie's disease, prostate cancer, prostate cancer news, sexual incontinence, urostop, Xofigo
